Call for Comment: SITC Breast Cancer Immunotherapy Clinical Practice Guideline This CPG will equip clinicians with the knowledge needed to utilize newly approved agents, including guidance on patient selection, biomarker testing, and management of immune-related toxicities, in addition to providing expert insight for what’s on the horizon in immunotherapy treatment of breast cancer.
Comments due on Monday, March 22.
The Women in Cancer Immunotherapy Network (WIN) Leadership Institute returns this summer with two opportunities to attend, July 12–13 or Aug. 2–3. The program celebrates and empowers emerging women leaders in the field of cancer immunotherapy. Apply for the opportunity to attend by March 30.
Advance your cancer immunotherapy research with a SITC Fellowship! Domestic and international early career investigators from academia and government are encouraged to apply. Applications are due April 2.
The Biomarkers Subcommittees, Clinical and Biomarkers Data Sharing, Resources and Useful Tools are pleased to announce publication of three manuscripts that encompass the state of the field and a look to the future.
SITC President Patrick Hwu, MD, recently sat down with BioNTech CEO Ugur Sahin, MD, discussing a range of topics, including the process to develop the SARS-CoV-2 vaccine in 11 months
Access SITC Surgery Committee’s Recent JITC Publication“Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee”
In Module 3, Immune Checkpoint Blockade, participants will cover the biological foundation of immune checkpoint blockade therapies as well as diving into their clinical use.
Review data presented at the 35th Anniversary Annual Meeting & Pre-Conference Programs in the SITC 2020 regular abstract pre-print published in the Journal for ImmunoTherapy of Cancer (JITC)! SITC welcomed over 5,200 cancer immunotherapy professionals to SITC 2020 this November, our first ever virtual annual meeting!
Comprised of several authoritative reviews of checkpoints beyond PD-1, this series, edited by Ana Carrizosa Anderson and Dario A.A. Vignali, promotes the tremendous research that is opening new pathways for treating patients with cancer.
Now Available: SITC Clinical Practice Guideline on Immunotherapy for the Treatment of Lymphoma
Join Brianna Hoffner, MSN, ANP-BC, AOCNP, and the thousands of other cancer immunotherapy professionals who proudly call themselves SITC members.
New Online Patient Course Available: Understanding Cancer Immunotherapy Access SITC’s dedicated resource for patients and caregivers to learn about cancer immunotherapy
Explore resources and educational opportunities for cancer patients and those who advocate for them.
Track the latest advancements and educational opportunities in tumor immunology and cancer immunotherapy.
Advance science, submit your manuscript and monitor the global progress of cancer immunotherapy research.
Purpose: Conversations directly relevant to patient care Audience: Practicing clinicians and staff, clinical investigators Suggested topics: demographics, clinical presentation, diagnostic testing, patient management issues/insights, patterns in ...
Purpose: Conversations directly relevant to research Audience: Laboratory and translational scientists Suggested topics: Data sharing, emerging literature, sample/tissue collection, model/reagent development, opportunities for collaboration, translational ...
Hello Women of SITC! I want to share information with you about the return of SITC's sought-after program just for women in our field: The Women in Cancer Immunotherapy Network (WIN) Leadership Institute . Applicants will be selected to attend one of ...
Donate today to support early career scientists who are emerging leaders seeking to advance research in the cancer immunotherapy field.
An open access, peer-reviewed journal, the Journal for ImmunoTherapy of Cancer (JITC) is the global voice of the society, producing original research articles, literature reviews and more on tumor immunology and cancer immunotherapy.
It is the mission of the Society for Immunotherapy of Cancer (SITC) to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com